201 related articles for article (PubMed ID: 38015710)
1. Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
Qiu Y; Ye W; Wang C; Zang J
Aging (Albany NY); 2023 Nov; 15(22):13312-13328. PubMed ID: 38015710
[TBL] [Abstract][Full Text] [Related]
2. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism-related genes and their relationships with immune infiltration.
Huang C; Li Y; Ling Q; Wei C; Fang B; Mao X; Yang R; Zhang L; Huang S; Cheng J; Liao N; Wang F; Mo L; Mo Z; Li L
FEBS Open Bio; 2023 Apr; 13(4):736-750. PubMed ID: 36814419
[TBL] [Abstract][Full Text] [Related]
4. Wnt pathway-related three-mRNA clinical outcome signature in bladder urothelial carcinoma: computational biology and experimental analyses.
Sun S; Wang Y; Wang J; Bi J
J Transl Med; 2021 Sep; 19(1):409. PubMed ID: 34579753
[TBL] [Abstract][Full Text] [Related]
5. Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma.
Zhou G; Qin G; Zhang Z; Zhao H; Xue L
Front Immunol; 2023; 14():1283792. PubMed ID: 37954600
[TBL] [Abstract][Full Text] [Related]
6. Uncovering the potential functions of lymph node metastasis-associated aberrant methylation differentially expressed genes and their association with the immune infiltration and prognosis in bladder urothelial carcinoma.
Gao W; Zhang J; Tian T; Fu Z; Bai L; Yang Y; Wu Q; Wang W; Guo Y
PeerJ; 2023; 11():e15284. PubMed ID: 37123010
[TBL] [Abstract][Full Text] [Related]
7. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
8. miR-628-5p is a Potential Novel Prognosis Biomarker, Associated with Immune Infiltration in Bladder Urothelial Carcinoma.
Huang H; Xu Q; Zhang Y; Zhou Y; Ma K; Luo Y
Curr Pharm Des; 2023; 29(31):2477-2488. PubMed ID: 37916623
[TBL] [Abstract][Full Text] [Related]
9. An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer.
Xiao Z; Cai Z; Deng D; Tong S; Zu X
Front Immunol; 2022; 13():1000321. PubMed ID: 36211349
[TBL] [Abstract][Full Text] [Related]
10. TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
Jiang Y; Zhu C; Huang H; Huang G; Fu B; Xi X
BMC Cancer; 2023 Aug; 23(1):716. PubMed ID: 37528357
[TBL] [Abstract][Full Text] [Related]
11. PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma.
Ni W; Yi L; Dong X; Cao M; Zheng J; Wei Q; Yuan C
Sci Rep; 2023 Feb; 13(1):2051. PubMed ID: 36739300
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
[TBL] [Abstract][Full Text] [Related]
13. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
Front Immunol; 2023; 14():955949. PubMed ID: 37006317
[TBL] [Abstract][Full Text] [Related]
15. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
Li C; Wan Z; Deng Q; Li Z; Wang Y
Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960
[TBL] [Abstract][Full Text] [Related]
16. Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
Li Y; Xu K; Zhang Y; Mao H; Qiu Q; Yan Z; Liu X; Du Y; Chen Z
BMC Cancer; 2023 Oct; 23(1):1021. PubMed ID: 37872487
[TBL] [Abstract][Full Text] [Related]
17. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
Front Immunol; 2022; 13():916800. PubMed ID: 35860239
[TBL] [Abstract][Full Text] [Related]
18. MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.
Zhu L; Liu X; Zhang W; Hu H; Wang Q; Xu K
BMC Cancer; 2022 May; 22(1):556. PubMed ID: 35581573
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
Zhu S; Li H; Fan Y; Tang C
BMC Urol; 2023 Jul; 23(1):124. PubMed ID: 37479989
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and
Dong Y; Xu C; Su G; Li Y; Yan B; Liu Y; Yin T; Mou S; Mei H
Front Immunol; 2023; 14():1122570. PubMed ID: 37275895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
